Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2008
Business Context: The Company is developing prGCD, a proprietary plant cell-expressed recombinant form of human glucocerebrosidase for the treatment of Gaucher disease, a rare lysosomal storage disorder.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical trial milestones rather than financial performance.
Material Changes
- Clinical Milestone: On December 19, 2008, the Company enrolled the first patient in a worldwide, multi-center, open-label, switchover trial to assess the safety and efficacy of prGCD.
- Phase III Status: The Company recently announced the completion of patient enrollment in a pivotal Phase III, multi-center, randomized, double-blind, parallel group, dose-ranging trial for naive patients with Gaucher disease.
Guidance, Outlook, and Risks
Outlook: Management is advancing prGCD through multiple clinical pathways, including a switchover trial and a completed enrollment Phase III trial for naive patients.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical trial outcomes. The success of the Company's strategy depends on the safety and efficacy results of these ongoing trials.
Key Facts for Investor Verification
- Confirmation of the first patient enrollment in the switchover trial for prGCD.
- Verification of the completion of patient enrollment in the pivotal Phase III trial for naive patients.
- Review of the attached press release (Exhibit 99.1) for detailed trial design and future timelines.